Drug Information

Drug General Information
Drug ID
D04ZBV
Former ID
DIB021197
Drug Name
VU-29
Synonyms
VU 29
Drug Type
Small molecular drug
Indication Discovery agent Investigative [541541]
Structure
Download
2D MOL

3D MOL
Formula
C22H16N4O3
InChI
InChI=1S/C22H16N4O3/c27-22(17-11-13-19(14-12-17)26(28)29)23-21-15-20(16-7-3-1-4-8-16)24-25(21)18-9-5-2-6-10-18/h1-15H,(H,23,27)
InChIKey
KIALCSMRIHRFPL-UHFFFAOYSA-N
PubChem Compound ID
11610682
PubChem Substance ID
16713551, 23720739, 76733317, 103489385, 104071486, 121502482, 125434168, 131549109, 134350226, 135697750, 163981449, 178103019, 187071973, 223684509, 227995493, 246707820, 252158078, 252160135
Target and Pathway
Target(s) Metabotropic glutamate receptor 5 Target Info Modulator (allosteric modulator) [528679]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Long-term potentiation
Retrograde endocannabinoid signaling
Glutamatergic synapse
Huntington's disease
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Metabotropic glutamate receptor group III pathway
Metabotropic glutamate receptor group I pathway
Endogenous cannabinoid signaling
Reactome G alpha (q) signalling events
Class C/3 (Metabotropic glutamate/pheromone receptors)
WikiPathways Hypothetical Network for Drug Addiction
GPCRs, Class C Metabotropic glutamate, pheromone
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signaling
References
Ref 541541(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6403).
Ref 528679Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses. Mol Pharmacol. 2007 May;71(5):1389-98. Epub 2007 Feb 15.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.